Harvard Bioscience (HBIO) Cash from Investing Activities (2010 - 2026)
Harvard Bioscience (HBIO) posted quarterly Cash from Investing Activities of -$620000.0 for Q1 2026, up 9.22% year-over-year from -$567640.8 in Q1 2025, and down 3.51% quarter-over-quarter from -$599000.0 in Q4 2025.
Harvard Bioscience (HBIO) Cash from Investing Activities (2010 - 2026) Analysis & Trends
Harvard Bioscience (HBIO) has reported Cash from Investing Activities for 17 consecutive years, with -$620000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash from Investing Activities rose 9.22% year-over-year to -$620000.0; the TTM figure through Mar 2026 stood at -$1.8 million (changed 0.11% YoY), while the FY2025 annual figure was -$1.9 million, down 38.62% from the prior year.
- Cash from Investing Activities slipped to -$620000.0 in Q1 2026 per HBIO's latest filing, from -$599000.0 in the prior quarter.
- Across five years, Cash from Investing Activities topped out at $458000.0 in Q2 2024 and bottomed at -$1.1 million in Q3 2024.
- Historically, Cash from Investing Activities has averaged -$424470.6 across 5 years, with a median of -$442000.0 in 2022.
- Annual changes were most pronounced in 2023 — Cash from Investing Activities tumbled 351.49% — and 2024, when it surged 173.28%.
- Harvard Bioscience's Cash from Investing Activities stood at -$235000.0 in 2022, then sank by 351.49% to -$1.1 million in 2023, then surged by 56.08% to -$466000.0 in 2024, then dropped by 28.54% to -$599000.0 in 2025, then declined by 3.51% to -$620000.0 in 2026.
- Business Quant data shows HBIO's Cash from Investing Activities at -$620000.0 in Q1 2026, -$599000.0 in Q4 2025, and -$348000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Intuitive Surgical | 134.13 Bn | 128.91 Bn | 1.96 Bn | -26.60 Mn |
| 2 | Becton Dickinson | 52.76 Bn | 51.90 Bn | 2.32 Bn | -241.00 Mn |
| 3 | Alcon | 35.81 Bn | 34.46 Bn | 1.68 Bn | -222.00 Mn |
| 4 | Resmed | 33.72 Bn | 32.25 Bn | 861.22 Mn | -383.65 Mn |
| 5 | Medline | 29.38 Bn | 26.70 Bn | 2.22 Bn | -461.00 Mn |
| 6 | West Pharmaceutical Services | 25.00 Bn | 24.57 Bn | 329.20 Mn | -43.20 Mn |
| 7 | Solventum | 15.46 Bn | 15.06 Bn | 1.29 Bn | -87.00 Mn |
| 8 | Cooper Companies | 14.88 Bn | 14.74 Bn | 735.40 Mn | -90.00 Mn |
| 9 | Baxter International | 13.58 Bn | 11.43 Bn | 1.03 Bn | -117.00 Mn |
| 10 | Harvard Bioscience | 33.45 Mn | 26.94 Mn | 12.63 Mn | -916,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -916,000.00 |
| Jun 30, 2026 | -916,000.00 |
| Mar 31, 2026 | -620,000.00 |
| Mar 31, 2026 | -620,000.00 |
| Dec 31, 2025 | -599,000.00 |
| Dec 31, 2025 | -599,000.00 |
| Sep 30, 2025 | -348,000.00 |
| Sep 30, 2025 | -348,000.00 |
| Jun 30, 2025 | -233,000.00 |
| Jun 30, 2025 | -233,000.00 |
| Mar 31, 2025 | -683,000.00 |
| Mar 31, 2025 | -683,000.00 |
| Dec 31, 2024 | -466,000.00 |
| Dec 31, 2024 | -466,000.00 |
| Sep 30, 2024 | -1.11 Mn |
| Sep 30, 2024 | -1.11 Mn |
| Jun 30, 2024 | 458,000.00 |
| Jun 30, 2024 | 458,000.00 |
| Mar 31, 2024 | -225,000.00 |
| Mar 31, 2024 | -225,000.00 |